Unique Minimally Invasive The UroLift System offers a non cutting, non heating prostate treatment for BPH up to 100cc, presenting a strong selling point to urologists seeking less invasive options that support faster recovery and outpatient procedures. Target outpatient surgical centers and hospitals with ambulatory surgery capacity; cross-sell with Teleflex's broader urology portfolio for integrated patient care.

Established Teleflex Channel As part of Teleflex Interventional Urology, UroLift benefits from an established global distribution and corporate backing, enabling faster access to hospitals and clinics, cross-sell opportunities with other Teleflex medical devices, and leverage Teleflex marketing and sales resources.

Patient Education Engine The UroLift Patient Ambassador Program indicates active patient education and demand generation; there is opportunity to collaborate on patient-led marketing and case studies, generating referrals from patients considering BPH treatment.

Innovation and Upgrades Launch of Advanced Tissue Control System in 2020 suggests ongoing R&D and potential upgrade or companion devices; sales opportunities exist to upsell ATC-enabled procedures or bundle with UroLift for comprehensive care.

Growth and Expansion Revenue in the mid-range with a mid-size employee base signals a scalable platform; room to grow through international expansion, hospital adoption, and upgrade cycles in aging male population with rising BPH prevalence.